AliveCor announced that the Food and Drug Administration (FDA) has cleared a new iteration of their KardiaMobile device, the KardiaMobile 6L, the first 6-lead personal electrocardiogram (ECG) device.

KardiaMobile is a portable ECG reader that works with smartphones and tablets; recently the device received expanded approval for detecting bradycardia and tachycardia.

The KardiaMobile 6L adds a third electrode (in addition to 2 electrodes for both thumbs) for the left knee or ankle, allowing for a greater view of electrical activity in the heart. This forms an inverted triangle of electrodes known as the Einthoven Triangle, or a 6-lead ECG.

Commenting on the new device, Eric Topol, MD, cardiologist, Founder and Director or Scripps Research Translational Institute, and author of the new book Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again, said, “I am impressed with the quality and simplicity of 6-lead smartphone ECG tracings which will unquestionably sharpen our ability to diagnose heart rhythm and conduction abnormalities. It’s a welcome and needed step forward for mobile heart diagnostics.”

Related Articles

The Company stated that the device will be available in June 2019 and can be preordered as of today. It can be paired to the Kardia app, which allows a physician to remotely monitor patients.

For more information visit Alivecor.com.